STOCK TITAN
  1. Home
  2. News
  3. ONCT

Oncternal Therapeutics Inc - ONCT STOCK NEWS

Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.

Oncternal Therapeutics Inc (ONCT) is a clinical-stage biopharmaceutical company advancing novel therapies for hematological malignancies and prostate cancer. This page aggregates official press releases and verified news about their innovative pipeline, including ROR1-targeted CAR T cell therapies and dual-action androgen receptor inhibitors.

Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. The curated collection includes announcements about trial initiations, scientific presentations, manufacturing developments, and collaborative research efforts in precision oncology.

All content is sourced directly from company filings and authorized publications, ensuring reliability for investment decision-making. Bookmark this page for streamlined access to ONCT's latest advancements in developing treatments for cancers with significant unmet needs.

News

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provides an update on its Phase 1/2 Study ONCT-808-101 for the ROR1-targeting autologous CAR T cell therapy ONCT-808 in patients with relapsed or refractory aggressive B-cell lymphoma. Initial results show promising complete and partial responses, with some adverse events. However, a fatal serious adverse event was reported in a patient at a higher dose level, prompting protocol changes and communication with the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
clinical trial
-
News

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) provided a business update and reported third quarter 2023 financial results. They announced the dosing of the first patient in the Phase 1/2 study for ONCT-534, a dual-action androgen receptor inhibitor, for advanced prostate cancer treatment. They also treated additional patients in the ongoing Phase 1/2 study for ONCT-808, an autologous CAR T cell therapy, for aggressive B-cell lymphoma. The company has $40.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023, with a cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
earnings
-
News

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) will report Q3 2023 financial results on November 9, 2023, after the U.S. financial markets close. The management will host a webcast at 2:00 p.m. PT to provide a business update and discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
earnings
News

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics receives Fast Track designation from FDA for ONCT-534 in the treatment of mCRPC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
clinical trial
-
News

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Rhea-AI Summary
Oncternal Therapeutics adds Dr. Matthew Smith to its Prostate Cancer Scientific Advisory Board to guide the clinical development of ONCT-534, a dual-acting androgen receptor inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
management
-
News

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics announces dosing of first patient in Phase 1/2 study of ONCT-534
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

Rhea-AI Summary
Oncternal Therapeutics establishes Prostate Cancer Scientific Advisory Board (SAB) to support the development of its dual-acting androgen receptor inhibitor, ONCT-534. Members of the SAB include world-renowned leaders in prostate cancer research. This development could positively impact the company's stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
management
-
News

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, a clinical-stage biopharmaceutical company, has obtained FDA IND clearance for ONCT-534, a dual-action androgen receptor inhibitor for the treatment of advanced prostate cancer. They have also dosed the first patient in their Phase 1/2 study for ONCT-808, a ROR1-targeting autologous CAR T cell therapy for aggressive B-cell lymphoma. The company has extended its cash runway into 2025 with $45.5 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
earnings
-
News

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

Rhea-AI Summary
Oncternal Therapeutics, Inc. (ONCT) to Report Q2 2023 Financial Results and Host Webcast for Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
earnings
News

Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

Rhea-AI Summary
Oncternal Therapeutics receives FDA authorization for Phase 1/2 study of ONCT-534 in metastatic castration-resistant prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
Stock ONCT logo
Oncternal Therapeutics Inc

Nasdaq:ONCT

ONCT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

ONCT Stock Data

1.56M
2.68M
9.23%
12.07%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO